IL297963A - Antagonists of the adenosine a2a receptor - Google Patents
Antagonists of the adenosine a2a receptorInfo
- Publication number
- IL297963A IL297963A IL297963A IL29796322A IL297963A IL 297963 A IL297963 A IL 297963A IL 297963 A IL297963 A IL 297963A IL 29796322 A IL29796322 A IL 29796322A IL 297963 A IL297963 A IL 297963A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- pyrazolo
- pyridyl
- chloro
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006823.5A GB202006823D0 (en) | 2020-05-07 | 2020-05-07 | Antagonist compounds |
| GBGB2019922.0A GB202019922D0 (en) | 2020-12-16 | 2020-12-16 | Antagonist compounds |
| PCT/GB2021/051106 WO2021224636A1 (en) | 2020-05-07 | 2021-05-06 | Antagonists of the adenosine a2a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297963A true IL297963A (en) | 2023-01-01 |
Family
ID=75977772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297963A IL297963A (en) | 2020-05-07 | 2021-05-06 | Antagonists of the adenosine a2a receptor |
| IL324071A IL324071A (en) | 2020-05-07 | 2025-10-19 | Antagonists of the adenosine a2a receptor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324071A IL324071A (en) | 2020-05-07 | 2025-10-19 | Antagonists of the adenosine a2a receptor |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12617796B2 (enExample) |
| EP (2) | EP4146654A1 (enExample) |
| JP (2) | JP7724239B2 (enExample) |
| KR (2) | KR20260083407A (enExample) |
| CN (2) | CN122010947A (enExample) |
| AU (1) | AU2021266433A1 (enExample) |
| BR (1) | BR112022022437A2 (enExample) |
| CA (1) | CA3181354A1 (enExample) |
| CL (1) | CL2022003055A1 (enExample) |
| CO (1) | CO2022017618A2 (enExample) |
| EC (1) | ECSP22091613A (enExample) |
| GB (1) | GB2609879B (enExample) |
| IL (2) | IL297963A (enExample) |
| MX (1) | MX2022013946A (enExample) |
| PE (1) | PE20230769A1 (enExample) |
| PH (1) | PH12022552987A1 (enExample) |
| WO (1) | WO2021224636A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023114157A2 (en) * | 2021-12-17 | 2023-06-22 | Merck Sharp & Dohme Llc | Pyrazolopyrimidine derivatives and methods of use thereof for the treatment of herpesviruses |
| CN116283994B (zh) * | 2021-12-20 | 2025-01-07 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的杂环化合物 |
| TWI861659B (zh) * | 2022-01-18 | 2024-11-11 | 大陸商江蘇亞堯生物科技有限公司 | 吡唑並嘧啶化合物及其組合物、製備方法和用途 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| AU2024338138A1 (en) * | 2023-09-08 | 2026-03-19 | Satellos Bioscience Inc. | Ap2 associated kinase 1 inhibitors and uses thereof |
| IL328105A (en) | 2023-10-30 | 2026-06-01 | Johnson & Johnson Entpr Innovation Inc | Safe administration of a2a rector antagonist |
| WO2025123251A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Crystalline forms of a2a receptor antagonist, preparation methods, and uses thereof |
| WO2025123253A1 (en) | 2023-12-13 | 2025-06-19 | Johnson & Johnson Enterprise Innovation Inc. | Pharmaceutical compositions of an a2a receptor antagonist |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| UY41082A (es) | 2024-03-28 | 2025-08-29 | Pi Industries Ltd | Compuestos bicíclicos condensados y su uso como agentes de control de plagas |
| CN120093763A (zh) * | 2025-03-25 | 2025-06-06 | 上海天龙生物科技有限公司 | 治疗前列腺疾病和腺体类散结节的药物组合物及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3910907A (en) | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| HK1044282A1 (zh) | 1998-12-18 | 2002-10-18 | Bristol-Myers Squibb Pharma Company | 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物 |
| AU2482100A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2057200A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6605623B1 (en) | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6525069B1 (en) | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| EP1205478A4 (en) | 1999-08-06 | 2004-06-30 | Takeda Chemical Industries Ltd | P38MAP KINASE INHIBITORS |
| CA2404384A1 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
| EP1294690A2 (en) | 2000-06-21 | 2003-03-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU2001271357A1 (en) | 2000-06-21 | 2002-01-02 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| WO2002051442A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| WO2002062792A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| PT1368355E (pt) | 2001-03-14 | 2006-09-29 | Gruenenthal Gmbh | Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos |
| CA2442428A1 (en) | 2001-03-28 | 2002-10-10 | Mark D. Wittman | Novel tyrosine kinase inhibitors |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| EP1402900A1 (en) | 2001-06-11 | 2004-03-31 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| JP2005510508A (ja) | 2001-11-08 | 2005-04-21 | 藤沢薬品工業株式会社 | アデノシンアンタゴニストとしてのチアゾールピリダジノン類 |
| CA2483306A1 (en) * | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| TWI349550B (en) | 2003-12-26 | 2011-10-01 | A thiazole derivative and adenosine a2a receptor antagonist containing the same | |
| CA2551867C (en) | 2003-12-31 | 2010-08-17 | Schering-Plough Ltd. | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JPWO2006070943A1 (ja) | 2004-12-28 | 2008-06-12 | 武田薬品工業株式会社 | 縮合イミダゾール化合物およびその用途 |
| US8178533B2 (en) * | 2005-06-01 | 2012-05-15 | Ucb Pharma, S.A. | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| EA201000046A1 (ru) * | 2007-06-21 | 2011-02-28 | Кара Терапеутикс, Инк. | Замещенные имидазогетероциклы |
| WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| EP2103614A1 (en) | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2402344A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| EP2402343A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
| EP2402345A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| WO2012100342A1 (en) * | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| US9199979B2 (en) | 2011-02-24 | 2015-12-01 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| CN104418821A (zh) | 2013-08-22 | 2015-03-18 | 四川大学华西医院 | 2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途 |
| ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| EP3227286B1 (de) * | 2014-12-02 | 2018-12-26 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| KR102706837B1 (ko) | 2016-04-15 | 2024-09-19 | 캔써 리서치 테크놀로지 리미티드 | Ret 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| US11608334B2 (en) * | 2017-02-08 | 2023-03-21 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| AU2021228284A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| MX2022012677A (es) | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| CA3174353A1 (en) | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| TWI782504B (zh) | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (三氟甲基)嘧啶-2-胺化合物 |
| GB202011996D0 (en) | 2020-07-31 | 2020-09-16 | Adorx Therapeutics Ltd | Antagonist compounds |
| GB202019622D0 (en) | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
| MX2023006728A (es) | 2020-12-16 | 2023-06-19 | New Frontier Labs Llc | Esteres de acido dicarboxilico para inducir un efecto analgesico. |
| PE20232040A1 (es) | 2020-12-16 | 2023-12-21 | New Frontier Labs Llc | Esteres de acidos dicarboxilicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d |
| LT4263545T (lt) | 2020-12-16 | 2026-07-27 | Amgen Inc. | Prmt5 inhibitoriai |
-
2021
- 2021-05-06 IL IL297963A patent/IL297963A/en unknown
- 2021-05-06 WO PCT/GB2021/051106 patent/WO2021224636A1/en not_active Ceased
- 2021-05-06 CN CN202511968176.0A patent/CN122010947A/zh active Pending
- 2021-05-06 PE PE2022002570A patent/PE20230769A1/es unknown
- 2021-05-06 KR KR1020267013983A patent/KR20260083407A/ko active Pending
- 2021-05-06 PH PH1/2022/552987A patent/PH12022552987A1/en unknown
- 2021-05-06 JP JP2022567895A patent/JP7724239B2/ja active Active
- 2021-05-06 BR BR112022022437A patent/BR112022022437A2/pt unknown
- 2021-05-06 MX MX2022013946A patent/MX2022013946A/es unknown
- 2021-05-06 KR KR1020227042714A patent/KR20230035236A/ko active Pending
- 2021-05-06 GB GB2217519.4A patent/GB2609879B/en active Active
- 2021-05-06 EP EP21726445.6A patent/EP4146654A1/en active Pending
- 2021-05-06 CN CN202180047824.2A patent/CN115996929B/zh active Active
- 2021-05-06 CA CA3181354A patent/CA3181354A1/en active Pending
- 2021-05-06 US US17/923,374 patent/US12617796B2/en active Active
- 2021-05-06 AU AU2021266433A patent/AU2021266433A1/en active Pending
- 2021-05-06 EP EP26172595.6A patent/EP4789672A2/en active Pending
-
2022
- 2022-11-04 CL CL2022003055A patent/CL2022003055A1/es unknown
- 2022-12-01 EC ECSENADI202291613A patent/ECSP22091613A/es unknown
- 2022-12-06 CO CONC2022/0017618A patent/CO2022017618A2/es unknown
-
2025
- 2025-08-04 JP JP2025130117A patent/JP2025183201A/ja active Pending
- 2025-10-19 IL IL324071A patent/IL324071A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023525762A (ja) | 2023-06-19 |
| JP7724239B2 (ja) | 2025-08-15 |
| AU2021266433A1 (en) | 2022-12-15 |
| EP4789672A2 (en) | 2026-08-12 |
| PE20230769A1 (es) | 2023-05-09 |
| GB202217519D0 (en) | 2023-01-04 |
| CN122010947A (zh) | 2026-05-12 |
| CO2022017618A2 (es) | 2023-02-16 |
| WO2021224636A1 (en) | 2021-11-11 |
| BR112022022437A2 (pt) | 2023-01-03 |
| KR20260083407A (ko) | 2026-06-05 |
| IL324071A (en) | 2025-12-01 |
| GB2609879A (en) | 2023-02-15 |
| US20230203041A1 (en) | 2023-06-29 |
| CL2022003055A1 (es) | 2023-07-07 |
| CA3181354A1 (en) | 2021-11-11 |
| CN115996929A (zh) | 2023-04-21 |
| EP4146654A1 (en) | 2023-03-15 |
| PH12022552987A1 (en) | 2024-02-26 |
| KR20230035236A (ko) | 2023-03-13 |
| MX2022013946A (es) | 2023-02-01 |
| CN115996929B (zh) | 2026-01-13 |
| ECSP22091613A (es) | 2023-03-31 |
| US12617796B2 (en) | 2026-05-05 |
| JP2025183201A (ja) | 2025-12-16 |
| GB2609879B (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12617796B2 (en) | Antagonists of the adenosine A2a receptor | |
| ES3037790T3 (en) | Antagonist compounds | |
| CN109195972B (zh) | 作为ret激酶抑制剂的杂环化合物 | |
| IL303492A (en) | Antagonists of the adenosine a2a receptor | |
| WO2022090711A1 (en) | Compounds as cd73 inhibitors | |
| US20250340565A1 (en) | Cd73 inhibitor compounds | |
| HK40130881A (en) | Antagonist compounds | |
| US20250243194A1 (en) | Antagonist of adenosine receptors |